---
document_datetime: 2026-02-04 16:51:53
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sugammadex-amomed-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: sugammadex-amomed-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 9.6686693
conversion_datetime: 2026-02-09 22:22:50.72113
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sugammadex Amomed

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber    | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | B.II.b.2.cReplacementor additionofa | 02/02/2026                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000323967                     | manufacturerresponsibleforimportation and/or batch release - B.1I.b.2.c.1 Not including batch control/testing - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     | PL   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|
| Variation type IB / EMA/VR/0000284375 | B.II.d.2 Change in testprocedure for the finished product - B.II.d.2.z Other changes - Accepted B.II.b.2 Change to importer,batch release arrangements andquality controltesting of the finished product-B.1I.b.2.a Replacementoradditionofasitewhere batch control/testing takes place - Accepted B.II.b.1Replacementor addition of a manufacturingsiteforpartor all of the manufacturing process of the finished product - B.1I1.b.1.a Secondary packaging site - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition)-Accepted B.II.d.2 Change in testprocedurefor the finishedproduct-B.II.d.2.d Other changes to a test procedure (including replacement or addition)- Accepted B.II.d.2 Change in test procedure for the | 25/09/2025 | N/A |      |

<div style=\"page-break-after: always\"></div>

| toa testprocedure(includingreplacement or addition)- Accepted batch size ranges) of the finished product - B.II.b.4.z Other changes, including change from single batch size to a range of batch sizes - Accepted B.II.b.3 Change in the manufacturing finished product-B.II.b.3.z Other changes-   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B.I1.b.4 Change in the batch size (including                                                                                                                                                                                                                                                        |
| process of the finished product, including an                                                                                                                                                                                                                                                       |
| intermediateused in themanufactureof the                                                                                                                                                                                                                                                            |
| Accepted                                                                                                                                                                                                                                                                                            |
| B.II.b.2 Change to importer,batch release arrangements and quality control testing of                                                                                                                                                                                                               |
| the finished product-B.II.b.2.a                                                                                                                                                                                                                                                                     |
| Replacement or addition of a site where                                                                                                                                                                                                                                                             |
| batch control/testing takes place -Accepted                                                                                                                                                                                                                                                         |
| B.II.b.1Replacement or addition of a                                                                                                                                                                                                                                                                |
| manufacturing site for part or all of the                                                                                                                                                                                                                                                           |
| manufacturing process of the finished                                                                                                                                                                                                                                                               |
| product - B.1I1.b.1.a Secondary packaging                                                                                                                                                                                                                                                           |
| site -Accepted                                                                                                                                                                                                                                                                                      |
| manufacturingsiteforpartorallofthe                                                                                                                                                                                                                                                                  |
| manufacturing process of the finished                                                                                                                                                                                                                                                               |
| product - B.1I.b.1.f Site where any                                                                                                                                                                                                                                                                 |
| manufacturingoperation(s)takeplace,                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|                                       | exceptbatchrelease,batchcontrol,and secondary packaging, for sterile medicinal products(including those that are aseptically manufactured)excludingbiological/ immunological medicinal products - Accepted                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000248398 | B.IACTIVESUBSTANCE-B.I.zSubstantial updates to Mod. 3.2.S or the ASMF - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 24/07/2025 |            |                        | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Variation type IB / EMA/VR/0000267132 | This was an applicationfor a group of variations. C.I.2 Change(s) in the Summary of Product Characteristics,LabellingorPackageLeaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.1.2.a Implementation of change(s) for which no new additional datais required to be submitted by theMAH-Accepted C.1.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change)-Accepted | 03/06/2025 | 23/06/2025 | SmPC, Labelling and PL | Toextendtheindicationtoincludethetreatmentof paediatric patients from birth up to less than 2 years of age, based on the final results of the paediatric study PN169(MK-8616-P169).As a result, sections 4.1, 4.2, 4.8, 5.1, and 5.2 of the SmPC have been updated accordingly. The Package Leaflethas alsobeenrevised toreflectthese changes.Thechangesfollowassessmentof the samechangesforthereferenceproductBridion.To update part I and VI of the RMP to include all paediatric patients, in line with the RMP of the referenceproduct,andtoaddthetableregarding Summaryofchangestotheriskmanagementplan overtime'toAnnex8ofPartVII. |

<div style=\"page-break-after: always\"></div>

|                                       | thetreatmentofpaediatricpatientsfrom birthup tolessthan2yearsof age,based on the final results of the paediatric study PN169 (MK-8616-P169).As a result, sections 4.1,4.2,4.8,5.1, and 5.2 of the SmPChavebeenupdatedaccordingly.The PackageLeaflethasalsobeenrevisedto reflectthese changes.The changesfollow assessment of the same changes for the reference product Bridion.In addition,the MAHtooktheopportunity tointroduce editorial changes to the PI in CZ, DA, DE, EL, ES,EE,FI,FR,HR,HU,LT,LV and RO to alignwiththePIofthereferenceproduct,to correctfor abbreviations,spellingand grammar mistakes, and to align with the QRD template. C.1.11.z - To update part I and VI of the RMP to include all paediatric patients, in line with the RMP of the referenceproduct,and to add thetable regarding'Summary of changes to the risk managementplanovertime'toAnnex8of Part VII.   |            |            |             |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| Variation type IB / EMA/VR/0000254268 | C.I.2Change(s)in theSummary ofProduct Characteristics,LabellingorPackageLeaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.1.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 24/03/2025 | 23/06/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| C.1.2.a (IB)-To update section 4.8 of the SmPC inorder to include information on hypersensitivity reactions associated with thesugammadex-rocuroniumcomplex. Furthermore,editorialchangestothe ProductInformationinvolvethecorrection of obvious mistakes, typographical errors and minor editorial adjustments for the following languages: CS, DE, EL, EN, ES,ET, FI, FR, HR,IS,IT,LT,MT, NO,PL,PT,RO,SK,SL and SV. Finally, section 6 of the PL has been updated with new phone number for Spanish andPortugueselocalrepresentatives.   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|